Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic cancer vaccines
M Saxena, SH van der Burg, CJM Melief… - Nature Reviews …, 2021 - nature.com
Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …
understanding of the breadth of tumour-associated antigens, the native immune response …
[HTML][HTML] Non-small cell lung cancer: current treatment and future advances
C Zappa, SA Mousa - Translational lung cancer research, 2016 - ncbi.nlm.nih.gov
Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …
MUC1: a multifaceted oncoprotein with a key role in cancer progression
S Nath, P Mukherjee - Trends in molecular medicine, 2014 - cell.com
The transmembrane glycoprotein Mucin 1 (MUC1) is aberrantly glycosylated and
overexpressed in a variety of epithelial cancers, and plays a crucial role in progression of …
overexpressed in a variety of epithelial cancers, and plays a crucial role in progression of …
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind …
TJ Lynch, I Bondarenko, A Luft… - Journal of clinical …, 2012 - ascopubs.org
Purpose Ipilimumab, which is an anti–cytotoxic T-cell lymphocyte-4 monoclonal antibody,
showed a survival benefit in melanoma with adverse events (AEs) managed by protocol …
showed a survival benefit in melanoma with adverse events (AEs) managed by protocol …
Association of survival and immune-related biomarkers with immunotherapy in patients with non–small cell lung cancer: A meta-analysis and individual patient–level …
Importance The beneficial role of immunotherapy and the clinical relevance of current
biomarkers in non–small cell lung cancer (NSCLC) remain inconclusive; thus, appropriate …
biomarkers in non–small cell lung cancer (NSCLC) remain inconclusive; thus, appropriate …
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
C Butts, MA Socinski, PL Mitchell, N Thatcher… - The lancet …, 2014 - thelancet.com
Background Effective maintenance therapies after chemoradiotherapy for lung cancer are
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer …
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer …
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Previously, clinical approaches to using the immune system against cancer focused on
vaccines that intended to specifically initiate or amplify a host response against evolving …
vaccines that intended to specifically initiate or amplify a host response against evolving …
Immunotherapy of cancer in 2012
JM Kirkwood, LH Butterfield, AA Tarhini… - CA: a cancer journal …, 2012 - Wiley Online Library
The immunotherapy of cancer has made significant strides in the past few years due to
improved understanding of the underlying principles of tumor biology and immunology …
improved understanding of the underlying principles of tumor biology and immunology …
[HTML][HTML] Recent developments of liposomes as nanocarriers for theranostic applications
H Xing, K Hwang, Y Lu - Theranostics, 2016 - ncbi.nlm.nih.gov
Liposomes are nanocarriers comprised of lipid bilayers encapsulating an aqueous core. The
ability of liposomes to encapsulate a wide variety of diagnostic and therapeutic agents has …
ability of liposomes to encapsulate a wide variety of diagnostic and therapeutic agents has …